Hikma Pharmaceuticals PLC (HIK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has a cash flow conversion efficiency ratio of 0.063x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX161.00 Million ≈ $19.59K USD) by net assets (GBX2.55 Billion ≈ $310.38K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hikma Pharmaceuticals PLC market capitalisation for the company's overall valuation and market capitalisation.
Hikma Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hikma Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Explore earnings quality score of Hikma Pharmaceuticals PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinmah Capital Bhd
KLSE:9776
|
-0.137x |
|
Phoenix Materials Co. Ltd
KQ:050090
|
-0.010x |
|
Cokal Ltd
AU:CKA
|
0.410x |
|
Balco Group AB
ST:BALCO
|
-0.119x |
|
ANAX Metals Ltd
AU:ANX
|
-0.076x |
|
YATRA ONLINE DL-0001
F:26Y
|
-0.006x |
|
OCR Group Bhd
KLSE:7071
|
-0.107x |
|
EDM Resources Inc
V:EDM
|
-0.067x |
Annual Cash Flow Conversion Efficiency for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual cash flow conversion efficiency of Hikma Pharmaceuticals PLC from 2002 to 2024. View today's stock price for Hikma Pharmaceuticals PLC for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX2.32 Billion ≈ $282.40K |
GBX564.00 Million ≈ $68.62K |
0.243x | -11.71% |
| 2023-12-31 | GBX2.21 Billion ≈ $268.77K |
GBX608.00 Million ≈ $73.98K |
0.275x | +11.55% |
| 2022-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX530.00 Million ≈ $64.49K |
0.247x | -4.59% |
| 2021-12-31 | GBX2.47 Billion ≈ $300.16K |
GBX638.00 Million ≈ $77.63K |
0.259x | +19.72% |
| 2020-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX464.00 Million ≈ $56.46K |
0.216x | -2.56% |
| 2019-12-31 | GBX2.13 Billion ≈ $259.04K |
GBX472.00 Million ≈ $57.43K |
0.222x | -12.51% |
| 2018-12-31 | GBX1.70 Billion ≈ $206.48K |
GBX430.00 Million ≈ $52.32K |
0.253x | -12.60% |
| 2017-12-31 | GBX1.53 Billion ≈ $185.91K |
GBX443.00 Million ≈ $53.90K |
0.290x | +138.57% |
| 2016-12-31 | GBX2.41 Billion ≈ $293.35K |
GBX293.00 Million ≈ $35.65K |
0.122x | -55.11% |
| 2015-12-31 | GBX1.35 Billion ≈ $164.50K |
GBX366.00 Million ≈ $44.53K |
0.271x | -22.55% |
| 2014-12-31 | GBX1.22 Billion ≈ $147.95K |
GBX425.00 Million ≈ $51.71K |
0.350x | +7.24% |
| 2013-12-31 | GBX1.03 Billion ≈ $125.81K |
GBX337.00 Million ≈ $41.00K |
0.326x | +51.70% |
| 2012-12-31 | GBX847.85 Million ≈ $103.16K |
GBX182.16 Million ≈ $22.16K |
0.215x | +67.18% |
| 2011-12-31 | GBX798.63 Million ≈ $97.17K |
GBX102.64 Million ≈ $12.49K |
0.129x | -30.52% |
| 2010-12-31 | GBX750.30 Million ≈ $91.29K |
GBX138.79 Million ≈ $16.89K |
0.185x | +19.78% |
| 2009-12-31 | GBX683.26 Million ≈ $83.13K |
GBX105.52 Million ≈ $12.84K |
0.154x | +62.51% |
| 2008-12-31 | GBX609.00 Million ≈ $74.10K |
GBX57.87 Million ≈ $7.04K |
0.095x | -6.41% |
| 2007-12-31 | GBX424.66 Million ≈ $51.67K |
GBX43.12 Million ≈ $5.25K |
0.102x | +18.42% |
| 2006-12-31 | GBX349.80 Million ≈ $42.56K |
GBX29.99 Million ≈ $3.65K |
0.086x | -24.65% |
| 2005-12-31 | GBX287.48 Million ≈ $34.98K |
GBX32.71 Million ≈ $3.98K |
0.114x | -49.70% |
| 2004-12-31 | GBX145.18 Million ≈ $17.66K |
GBX32.84 Million ≈ $4.00K |
0.226x | -25.43% |
| 2003-12-31 | GBX60.47 Million ≈ $7.36K |
GBX18.35 Million ≈ $2.23K |
0.303x | +1.52% |
| 2002-12-31 | GBX48.03 Million ≈ $5.84K |
GBX14.35 Million ≈ $1.75K |
0.299x | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more